NASDAQ:EVFM Evofem Biosciences (EVFM) Stock Price, News & Analysis $0.0075 0.00 (-5.06%) As of 03:50 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsNews and TrendsSEC Filings About Evofem Biosciences Stock (NASDAQ:EVFM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Evofem Biosciences alerts:Sign Up Key Stats Today's Range$0.0075▼$0.007950-Day Range$0.0070▼$0.008552-Week Range$0.00▼$0.02Volume62,507 shsAverage Volume205,018 shsMarket Capitalization$993.98 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Evofem Biosciences, Inc. is a women’s health biopharmaceutical company focused on developing and commercializing nonhormonal contraceptive products. Its primary product is Phexxi, a prescription, on-demand vaginal gel designed to prevent pregnancy by maintaining an acidic vaginal environment that reduces sperm motility. Phexxi was approved by the U.S. Food and Drug Administration in 2020 and launched in the United States later that year. The company has positioned Phexxi as a hormone-free contraceptive option for women who prefer not to use hormonal birth control or intrauterine devices. Evofem’s activities have primarily centered on the U.S. market, including product commercialization, physician and consumer education, and efforts to expand access through health care providers and pharmacies. Evofem Biosciences historically traded on the Nasdaq under the symbol EVFM. The company filed for Chapter 11 bankruptcy protection in 2022 and subsequently pursued a restructuring intended to support the continued commercialization of Phexxi. Saundra Pelletier has served as the company’s chief executive officer and has been a prominent leader in its development and commercialization efforts.AI Generated. May Contain Errors. Read More Receive EVFM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evofem Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EVFM Stock News HeadlinesEvofem Biosciences Adds Additional Manufacturing Capacity for PHEXX® to Support Global Growth StrategySeptember 23, 2026 | businesswire.comEvofem Biosciences Celebrates Shipment of Its 500,000th Unit of PHEXX®, Representing Hormone-Free Protection from Unintended Pregnancy for 6 Million Acts of SexJuly 23, 2026 | finance.yahoo.comHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end.October 12 at 1:00 AM | Banyan Hill Publishing (Ad)Evofem Biosciences Updates Investors via New PresentationJuly 20, 2026 | tipranks.comEvofem Biosciences Inc. (EVFM)July 12, 2026 | nasdaq.comHUB Cyber Security Expands Into Women’s Health With Zero-Cash Acquisition of Evofem Notes, Advances Balance Sheet TurnaroundJuly 1, 2026 | finance.yahoo.comEvofem Biosciences Inc. (EVFM) SEC FilingsJune 23, 2026 | nasdaq.comEvofem Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 18, 2026 | businesswire.comSee More Headlines EVFM Stock Analysis - Frequently Asked Questions How have EVFM shares performed this year? Evofem Biosciences' stock was trading at $0.0092 at the start of the year. Since then, EVFM shares have decreased by 18.5% and is now trading at $0.0075. How were Evofem Biosciences' earnings last quarter? Evofem Biosciences, Inc. (NASDAQ:EVFM) posted its quarterly earnings results on Friday, June, 16th. The biotechnology company reported ($1.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($15.00) by $13.15. The biotechnology company earned $5.81 million during the quarter. Evofem Biosciences had a negative net margin of 46.42% and a negative trailing twelve-month return on equity of 91.97%. When did Evofem Biosciences' stock split? Evofem Biosciences's stock reverse split before market open on Thursday, May 18th 2023.The 1-125 reverse split was announced on Thursday, May 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Evofem Biosciences? Shares of EVFM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Evofem Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evofem Biosciences investors own include Tesla (TSLA), NIO (NIO), Plug Power (PLUG), Meta Platforms (META), Sorrento Therapeutics (SRNE), NVIDIA (NVDA) and Ford Motor (F). Company Calendar Last Earnings6/16/2023Today10/12/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:EVFM CIK1618835 Webwww.evofem.com Phone(858) 550-1900Fax844-828-2010Employees29Year Founded2007Profitability EPS (Trailing Twelve Months)($0.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$52.98 million Net Margins-46.42% Pretax Margin-46.42% Return on Equity-91.97% Return on Assets-61.93% Debt Debt-to-Equity RatioN/A Current Ratio0.11 Quick Ratio0.09 Sales & Book Value Annual Sales$11.39 million Price / Sales0.09 Cash FlowN/A Price / Cash FlowN/A Book Value($2.64) per share Price / Book0.00Miscellaneous Outstanding Shares132,530,000Free Float113,118,000Market Cap$993.98 thousand OptionableNot Optionable Beta-1.37 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:EVFM) was last updated on 10/12/2026 by MarketBeat.com Staff. From Our PartnersA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredMy biggest prediction yet?!James Altucher called Facebook's rise past 100 billion dollars in 2007 and Apple's run to a trillion years lat...Paradigm Press | SponsoredThe AI Stock to Keep an Eye on Before Election Day (See Why)In 2019, Charles Mizrahi named Marvell Technology his top AI pick. It's since climbed 1300 percent. Now he'...Prosperity Research | SponsoredTrump To Relaunch USD?President Trump's summit with Xi Jinping drew headlines for tariffs and trade truces, but the real story may b...Porter & Company | SponsoredThis high yielding “gold annuity” is starting to move…Garrett Goggin, a 20+ year gold analyst, has called major moves before: Montage Gold up 2,567%, G2 Goldfields ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evofem Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evofem Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EVFM Stock Alerts